搜尋
Tenax Therapeutics Inc
TENX添加自選
14.520USD
+0.820+5.99%
收盤 07-31 16:00（美東）報價延遲15分鐘
463.91M總市值
虧損本益比TTM
關於 Tenax Therapeutics Inc 公司
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc簡介
公司代碼TENX
公司名稱Tenax Therapeutics Inc
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
員工數量4
證券類型Ordinary Share
年結日Oct 28
公司地址101 Glen Lennox Drive
城市CHAPEL HILL
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編27517
電話19198552100
網址http://www.tenaxthera.com/
公司代碼TENX
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
Tenax Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
常見問題
Tenax Therapeutics Inc的前五大股東是誰？
Tenax Therapeutics Inc的前五大股東如下：Dr. Stuart Rich, M.D.
有多少機構持有Tenax Therapeutics Inc(TENX)的股份？
截至2026Q1，共有74家機構持有Tenax Therapeutics Inc的股份，合計持有的股份價值約為11.71M，占公司總股份的51.15% 。與2025Q4相比，機構持股有所增加，增幅為5305648.00。